Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dezima Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001

Published: Friday, August 30, 2013
Last Updated: Friday, August 30, 2013
Bookmark and Share
TULIP study will investigate the effects of different doses of DEZ-001 on CVD biomarkers.

Dezima Pharma has announced the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease (CVD) in patients with mild dyslipidaemia.

The TULIP (“TA-8995: its Use in patients with mild dysLIPidemia”) study will take place in specialized centres across Denmark and the Netherlands and will investigate the effects of different doses of DEZ-001 on established CVD biomarkers over a 3 month dosing period.

DEZ-001 is a CETP inhibitor that has already demonstrated clinically relevant improvements on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels as well as other lipid parameters in healthy volunteers.

Professor John Kastelein, Chief Scientific Officer and founder of Dezima, commented, “I am very pleased that the TULIP study has kicked off with this very promising new compound for patients with dyslipidemia. If successful, this trial will pave the way for larger scale Phase 3 pivotal clinical trials.”

“The start of the TULIP study is an exciting milestone for Dezima Pharma,” Rob de Ree, CEO of Dezima added.

Ree continued, “Being the most potent CETP inhibitor in clinical development with excellent safety, pharmacokinetic and pharmacodynamic properties we firmly believe that our compound can further improve the outcome for patients suffering from cardiovascular disease due to dyslipidaemia.”

Dezima Pharma was founded in 2012 by John J.P. Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Centre, University of Amsterdam.

The Company recently raised €14.2m from a Series A financing with participation of Forbion Capital Partners, BioGeneration Ventures and New Science Ventures, and a loan from the Agentschap NL, an agency of the Dutch Ministry of Economic Affairs.

Dezima Pharma focuses on the development of novel products to treat dyslipidemic patients suffering from cardiovascular disease.

Its lead program DEZ-001 involves the development of the CETP inhibitor TA-8995, which was in-licensed from Mitsubishi Tanabe Pharma Corporation.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dezima In-Licenses CETP Inhibitor Program from MTPC
World-renowned dyslipidemia experts join Dezima’s Scientific Advisory Board.
Thursday, April 25, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Disordered Protein 'Shape Shifts' to Avoid Crowding
Study suggests disordered protein escapes from the cell membrane when it runs out of space.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Antibodies Block Norovirus’ Entrance into Cells
Scientists have uncovered a mechanism in the human body that targets and successfully blocks noroviruses.
Cancer's Taste for Fat
Researchers discovered signalling pathway for fat burning is disrupted in certain cancers.
Space Research Fighting Cancer
JPL and National Cancer Institute renew Big Data partnership that 'learns' data similarities.
"Pac-man Protein" May Aid the Fight Against Cancer
Scientists at the University of Sheffield have identified a protein which causes cells to eat their dying neighbours, helping to prevent inflammation – something which is vital in the fight to stop cancer spreading.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!